Trimethoprim
Small molecule targets SLC19A3 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BACTRIM | — | 1973-07-30 | fda.gov ↗ |
Trials 42 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 42 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07228702 Background | Jan 2026 → Oct 2027 expected | pulmonary non-tuberculous mycobacterial infection | Vancouver Coastal Health | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT05063422 Background | Aug 2022 → Aug 2023 | — | Altamash Institute of Dental Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01967758 Background | Jan 2014 → Jun 2018 | anaplastic astrocytoma, brain neoplasm, glioblastoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT01469637 Background | Nov → Dec 2011 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT02188472 Comparator | Nov 2010 → Feb 2011 | disorder of defective peroxisome oxidative status | Henrik Enghusen Poulsen | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01632891 Background | Jan 2014 → Jun 2016 | HIV infectious disease, parasitemia | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 1/2 | NCT00141037 Background | Mar 2004 → Sep 2006 | kidney disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT00078559 Background | Nov 2003 → Feb 2010 | kidney disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05835479 Comparator | Nov 2023 → May 2025 overdue | pneumocystosis | Mundipharma Research Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT05702762 Comparator | Oct 2022 → Jun 2023 | cystitis | Mercy Health Ohio | Unknown | No outcome recorded |
| Phase 2 | NCT05488340 Background | Jul 2022 → Jun 2026 overdue | urinary tract infection | Locus Biosciences | Recruiting | No outcome recorded |
| Phase 2 | NCT02734732 Comparator | Apr 2015 → Apr 2020 | prostatitis | Umeå University | Unknown | No outcome recorded |
| Phase 2 | NCT01757236 Comparator | Oct 2012 → Apr 2016 | periprosthetic joint infection | University Hospital, Tours | Unknown | No outcome recorded |
| Phase 2 | NCT01631617 Comparator | Sep 2012 → Jan 2027 expected | atopic eczema | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Recruiting | No outcome recorded |
| Phase 2 | NCT00014911 Background | Apr 2001 → Jun 2005 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05224401 Comparator | May 2023 → Sep 2027 expected | bacterial urinary tract infection | Lund University | Recruiting | No outcome recorded |
| Phase 3 | NCT02282293 Comparator | Dec 2014 → May 2016 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT02021006 Comparator | Dec 2013 → Jan 2020 | chronic kidney disease, renal hypodysplasia/aplasia 1, vesicoureteral reflux | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
| Phase 3 | NCT01595438 Background | Oct 2012 → Aug 2014 | acute pyelonephritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01599806 Background | Oct 2012 → Aug 2014 | acute pyelonephritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00933049 Comparator | Jul 2007 → Jan 2008 | pneumonia | Makerere University | Completed | No outcome recorded |
| Phase 3 | NCT00405704 Comparator | May 2007 → Jun 2013 | urinary tract infection, vesicoureteral reflux | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00324922 Comparator | May 2006 → May 2007 | methicillin-resistant staphylococcus aureus infectious disease, osteomyelitis | University of Washington | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT05719285 Comparator | Dec 2022 → Jun 2023 | overactive bladder | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT05331664 Comparator | Jul 2022 → Jul 2026 overdue | rhegmatogenous retinal detachment | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 4 | NCT04285320 Comparator | Mar 2021 → Apr 2023 | urinary tract infection | Atlantic Health System | Unknown | No outcome recorded |
| Phase 4 | NCT03235947 Background | Sep 2016 → Nov 2017 | bacteriuria, urinary tract infection | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Completed | No outcome recorded |
| Phase 4 | NCT03077711 Comparator | Jun 2016 → Jun 2019 | urinary tract infection | Endeavor Health | Completed | No outcome recorded |
| Phase 4 | NCT01820897 Comparator | Apr 2013 → Mar 2015 | bacteriuria, transplant rejection, urinary tract infection | JOSE MANUEL ARREOLA GUERRA | Completed | No outcome recorded |
| Phase 4 | NCT03877289 Background | Oct 2008 → Jul 2014 | cystitis | University of Calgary | Completed | No outcome recorded |
| Phase 4 | NCT00636935 Background | Feb 2008 → Aug 2013 | pneumocystosis | George Washington University | Withdrawn | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT05268120 Comparator | Jul 2022 → May 2028 expected | methicillin-resistant staphylococcus aureus infectious disease | Leiden University Medical Center | Recruiting | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT02944825 Comparator | Jan 2016 → Jan 2025 | urinary tract infection, urolithiasis | University of California, San Diego | Completed | No outcome recorded |
| — | NCT04306731 Comparator | Sep 2014 → Apr 2017 | urinary tract infection | University of Sulaimani | Completed | No outcome recorded |
| — | NCT01507974 Comparator | Jan 2012 → Jul 2014 | pregnancy disorder | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01843920 Background | Jun 2011 → Apr 2013 | — | Jason Hsu, MD | Completed | No outcome recorded |
| — | NCT01140516 Comparator | Jul 2010 → Sep 2024 | hydronephrosis, urinary tract infection | McMaster University | Unknown | No outcome recorded |
| — | NCT00976963 Comparator | Sep 2009 → Dec 2016 | urinary tract infection | University of Washington | Completed | No outcome recorded |
| — | NCT00822692 Comparator | Jul 2008 → Jun 2009 | abscess, methicillin-resistant staphylococcus aureus infectious disease | 59th Medical Wing | Completed | No outcome recorded |
| — | NCT00002002 Background | — | HIV infectious disease, pneumocystosis | Lederle Laboratories | Completed | No outcome recorded |
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 85 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trimethoprim | “AIDS patients with TE were randomly divided into 3 groups that received a 6-week course of either pyrimethamine (50 mg/day or 100 mg/day) plus sulfadiazine (4 g/day) and...” NCT00367081 ↗81“Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile,...” NCT03877289 ↗ “A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole...” NCT01967758 ↗ “Participants will receive a single oral dose of either Bactrim (800 mg sulfamethoxazole + 160 mg trimethoprim) or if allergic to sulfonamides, a single oral dose of Macrobid...” NCT07501065 ↗ “Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses: * less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim * greater than...” NCT01086878 ↗ “Patients randomized to the "Procedural Antibiotics Only" arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first...” NCT03508921 ↗ “Oral dose regimen for simple urinary tract infection: Including cephalexin, cefdinir, sulfamethoxazole/trimethoprim, and nitrofurantoin at appropriate dose, frequency, and duration” NCT05702762 ↗ “Antimicrobials included co-trimoxazole (trimethoprim 160 mg/sulfamethoxazole 800 mg twice daily plus folic acid 5 mg daily, n = 128) or doxycycline” PMID 33974018 ↗ May 2021 “800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days” NCT01469637 ↗ “Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults” NCT06397781 ↗ “one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension.” NCT05438082 ↗ “we randomized adults to oral trimethoprim-sulfamethoxazole or placebo after uncomplicated abscess incision and drainage.” PMID 20346539 ↗ Mar 2010 “co-trimoxazole will also be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day” NCT05835479 ↗ “800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery” NCT00970879 ↗ “TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.” NCT05488340 ↗ “antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone)” NCT00636935 ↗ “The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim” NCT01843920 ↗ “Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab; 800mg/160mg BID x 3 days” NCT00976963 ↗ “4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily” NCT00522821 ↗ “Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure” NCT05719285 ↗ “8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole” NCT00933049 ↗ “Trimethoprim (200mg twice daily)” NCT07202949 ↗ “Trimethoprim daily (100 mg)” NCT04285320 ↗ “T rimethoprim” NCT02099240 ↗ |
| Known as | BW 56-72 | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | BW 72U | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Infectotrimet | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Ledatrim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Monotrim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | NIH-204 | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | NSC-106568 | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Polymyxin/Trimethoprim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05331664 ↗ |
| Known as | Primsol | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Proloprim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Proloprin | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Syraprim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | TCMDC-125538 | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Tiempe | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | TMP | “sulfamethoxazole/trimethoprim (SMX/TMP)” NCT00000640 ↗1“TMP/SMZ(trimethoprim/sulfisoxazole)” NCT03978559 ↗ |
| Known as | TMP/SMZ | “Trimethoprim/sulfamethoxazole (TMP/SMZ)” NCT01631617 ↗ |
| Known as | Trimethoprim component of bactrim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of bactrim ds | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of bactrim pediatric | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of co-trimoxazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of cotrim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of cotrim d.s. | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of septra | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of sulfamethoprim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of sulfatrim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of sulmeprim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim component of uroplus | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | TRIMETHOPRIM HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | TRIMETHOPRIM MALEIC ACID SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | TRIMETHOPRIM OXALIC ACID SALT DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | TRIMETHOPRIM SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim sulfate component of polytrim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprim/sulfamethoxazole (TMP/SMZ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01631617 ↗ |
| Known as | Trimethoprime | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimethoprimum | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimetoprima | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimogal | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimopan | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimpex | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Trimpex 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Triprimix 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Known as | Wellcoprim | ChEMBL registry synonym — accepted as the source's own label CHEMBL22 ↗ |
| Action | Inhibit | “trimethoprim, have been shown to interrupt function of the SLC19A3 gene” NCT03746106 ↗ |
| Modality | Small molecule | — CHEMBL22 ↗ |
| Route | Oral | “two oral treatments for mild to moderate Pneumocystis carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a standard treatment program of...” NCT00000640 ↗ |
| Target | SLC19A3 | “Certain drugs, like metformin and trimethoprim, have been shown to interrupt function of the SLC19A3 gene.” NCT03746106 ↗ |